Literature DB >> 9602983

Statistical principles for clinical trials.

R Kay.   

Abstract

If a trial is to be well designed, and the conclusions drawn from it valid, a thorough understanding of the benefits and pitfalls of basic statistical principles is required. When setting up a trial, appropriate sample-size calculation is vital. If initial calculations are inaccurate, trial results will be unreliable. The principle of intent-to-treat in comparative trials is examined. Randomization as a method of selecting patients to treatment is essential to ensure that the treatment groups are equalized in terms of avoiding biased allocation in the mix of patients within groups. Once trial results are available the correct calculation and interpretation of the P-value is important. Its limitations are examined, and the use of the confidence interval to help draw valid conclusions regarding the clinical value of treatments is explored.

Entities:  

Mesh:

Year:  1998        PMID: 9602983     DOI: 10.1177/030006059802600201

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

1.  Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials.

Authors:  Sandra Castro-Pearson; Chap T Le; Xianghua Luo
Journal:  Contemp Clin Trials       Date:  2022-02-14       Impact factor: 2.261

2.  Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.

Authors:  Marian Mitroiu; Steven Teerenstra; Katrien Oude Rengerink; Frank Pétavy; Kit C B Roes
Journal:  Pharm Stat       Date:  2022-06-09       Impact factor: 1.234

3.  Effect of combining therapy with traditional chinese medicine-based psychotherapy and herbal medicines in women with menopausal syndrome: a randomized controlled clinical trial.

Authors:  Hongyan Yang; Jing Yang; Zehuai Wen; Qinglin Zha; Guangning Nie; Xuchun Huang; Chunlin Zhang; Aiping Lu; Miao Jiang; Xiaoyun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-10       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.